Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase ( NTRK) gene fusions in larotrectinib (laro) clinical trials

被引：1
|
作者：
Rudzinski, Erin R.
Ladanyi, Marc
Ritterhouse, Lauren L.
Sahm, Felix
Norenberg, Ricarda
Zheng, Hong
Chen, Chi
Bernard-Gauthier, Vadim
Brega, Nicoletta
Van Tilburg, Cornelis M.
Lin, Jessica J.
Brose, Marcia S.
Lassen, Ulrik N.
McDermott, Ray
Laetsch, Theodore W.
Hong, David S.
Drilon, Alexander
Roy-Chowdhuri, Sinchita
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT228
引用
收藏
页数：3
相关论文
共 21 条
  • [11] ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
    Urso, Loredana
    Vernaci, Grazia
    Carlet, Jessica
    Lo Mele, Marcello
    Fassan, Matteo
    Zulato, Elisabetta
    Faggioni, Giovanni
    Menichetti, Alice
    Di Liso, Elisabetta
    Griguolo, Gaia
    Falci, Cristina
    Conte, Pierfranco
    Indraccolo, Stefano
    Guarneri, Valentina
    Dieci, Maria Vittoria
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [12] Association between the hypothalamic-pituitary-adrenocortical (HPA) axis dysregulation in patients with major depression and polymorphisms in the brain derived neurotropic factor (BDNF) and neurotrophic tyrosine kinase receptor 2 (NTRK2) gene
    Zill, P
    Baghai, TC
    Zwanzger, PM
    Schüle, C
    Eser, D
    Möller, HJ
    Rupprecht, R
    Bondy, B
    PHARMACOPSYCHIATRY, 2005, 38 (05) : 287 - 287
  • [13] Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.
    Nakamura, Yoshiaki
    Taniguchi, Hiroya
    Bando, Hideaki
    Kato, Ken
    Esaki, Taito
    Komatsu, Yoshito
    Takahashi, Naoki
    Ueno, Makoto
    Kagawa, Yoshinori
    Nishina, Tomohiro
    Kato, Takeshi
    Yamamoto, Yoshiyuki
    Furuse, Junji
    Denda, Tadamichi
    Kawakami, Hisato
    Oki, Eiji
    Sunakawa, Yu
    Satoh, Taroh
    Yoshino, Takayuki
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [14] Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts).
    Benavides, Manuel
    Alcaide, Julia
    Alvarez, Martina
    Torres, Esperanza
    Sevilla, Isabel
    Calle, Silvia Gil
    Reyna, Carmen
    Ales, Inmaculada
    Duran, Gema
    Wolman, Roberto
    Cazorla, Mireya
    Gallego, Pedro Jimenez
    Lopez, Irene
    Cantero, Alexandra
    Godoy, Ana
    Lanman, Richard B.
    Faull, Iris
    Odegaard, Justin
    Kim, Il Jin
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [15] Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.
    Nakamura, Yoshiaki
    Taniguchi, Hiroya
    Bando, Hideaki
    Esaki, Taito
    Komatsu, Yoshito
    Kato, Ken
    Takahashi, Naoki
    Kagawa, Yoshinori
    Kato, Takeshi
    Nishina, Tomohiro
    Satoh, Taroh
    Oki, Eiji
    Sunakawa, Yu
    Shiozawa, Manabu
    Yamamoto, Yoshiyuki
    Kawakami, Hisato
    Denda, Tadamichi
    Ohtsu, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [16] Analysis of BRAF V600E mutation status - concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapy
    Haselmann, V. H.
    Gebhardt, C.
    Brechtel, I.
    Duda, A.
    Sucker, A.
    Utikal, J.
    Schadendorf, D.
    Neumaier, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [17] Analysis of BRAF V600E mutation status - concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapy
    Haselmann, V
    Gebhardt, C.
    Brechtel, I
    Duda, A.
    Sucker, A.
    Utikal, J.
    Schadendorf, D.
    Neumaier, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 36 - 36
  • [18] Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.
    Deng, Yanhong
    Zhao, Weiwei
    Yang, Liu
    Ling, Jiayu
    Mao, Linlin
    Hu, Huabin
    Cai, Yue
    Zhang, Jianwei
    Yu, Shihui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [19] Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.
    Ohba, Akihiro
    Nakamura, Yoshiaki
    Taniguchi, Hiroya
    Ikeda, Masafumi
    Bando, Hideaki
    Mizuno, Nobumasa
    Kato, Ken
    Morizane, Chigusa
    Nishina, Tomohiro
    Ueno, Makoto
    Furuse, Junji
    Hara, Hiroki
    Denda, Tadamichi
    Kawakami, Hisato
    Esaki, Taito
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Komatsu, Yoshito
    Yoshino, Takayuki
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [20] High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program
    Park, Sehhoon
    Olsen, Steve
    Ku, Bo Mi
    Lee, Min-Sang
    Jung, Hyun-Ae
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Choi, Yoon-La
    Ahn, Myung-Ju
    CANCER, 2021, 127 (16) : 3019 - 3028
123